Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Additional experimental and large-scale clinical designs with optimal dose and duration of homocysteine-lowering treatment are needed to definitively prove that homocysteine is responsible for the increased risk of cardiovascular disease, mostly of atherosclerosis
Silencing DKK1 has demonstrated the potential to inhibit tumor development in a CD8 + T cell-dependent approach, indicating its role in immune modulation
Watanabe, K
(2015, May 1)
US$ 24.64
US$ 20.55
US$ 29.53
US$ 20.64
